CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

• March 11, 2026

Oculomics: Beyond the Buzzword

Joseph J. Pizzimenti, OD, FAAO, FORS, discusses the capabilities of oculomics in retina and neuro-ophthalmology,

• by Sarah Fackler, managing editor, Optometric Management

• June 17, 2026

• 6 min

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

• by Kathryn Wighton

• July 7, 2026

• 6 min

Proinflammatory Epstein–Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis

• by Malina Behrens, Paula Terroba-Navajas, Eline A.J. Willemse, Sabine Schädelin, Manuel Comabella, Christian Münz, Gordan Lauc, Yannic Bartsch, Jens Kuhle, Jan D. Lünemann

• June 17, 2026